This month we saw the addition of 4 new members to the Anti-infective Drugs Advisory Committee! This committee is now only has 1 vacancy. The new members are.
This month we saw the addition of 4 new members to the Anti-infective Drugs Advisory Committee! This committee is now only has 1 vacancy. The new members are:
The Ani-infective Drugs Advisory Committee is scheduled for two meetings for the month of October. Click HERE to view the meeting announcement for one of their meetings regarding the safety and effectiveness of the new drug application (NDA) 204684 for miltefosine capsules, submitted by Paladin Therapeutics, Inc. Click HERE to view the entire FDA Advisory Committee Calendar!
4 new members were also added to the Drug Safety and Risk Management Advisory Committee. The new members are:
Dr. Bart Clarke departed from the Reproductive Health Drugs Advisory Committee and was replaced by Amy H. Herring, ScD, leaving the number of vacancies the same.
Furthermore, we saw the additions of Stuart Rich, M.D. to the Cardiovascular and Renal Drugs Advisory Committee, Jessie L-S Au, Ph.D. to the Pharmaceutical Science and Clinical Pharmacology Advisory Committee, Bernard F. Cole, Ph.D. to the Oncologic Drugs Advisory Committee, and Diana Hallare, MPH to the Endorcrinologic and Metabolic Drugs Advisory Committee as a Consumer Representative.
Stay tuned for our next AdComm Roll Call Special where we will put the spotlight on the FDA’s one and only Dermatologic and Opthalmic Drugs Advisory Committee!!!
ISS has over a decade of experience in developing regulatory strategies including support for FDA Advisory Committee meetings. We are involved in more FDA AdComms per year than even the largest pharmaceutical companies. For more information on how ISS can help you prepare for your next meeting, contact firstname.lastname@example.org
Interested in learning about ISS’ expert approach to Advisory Committee Meetings? Click below in order to find out for yourself!
Over the past few years, the number of ex-US manufacturers submitting a Class II exempt 510k device registration has increased substantially. For companies with medical devices that are approved and successful in a foreign market, the logical next step is to introduce their product into the US, which has one of the most lucrative healthcare markets in the world. Read more
FDA advisory committee meetings are important regulatory events for many manufacturers on the path to marketing approval. These meetings can quite literally result in the approval or rejection of a product based on the panel’s vote. Read more
One of the main challenges our clients face is determining which regulatory pathway is best for their products. For example, what if an OTC product has a Monograph active ingredient but that ingredient is present at a different amount than the permitted amount? Or what if the label claims a novel indication not specified in a Monograph? If you are debating pursuit of either regulatory pathway for your OTC drug, it is critical to consider cost, timeline, and label claims to ensure your products has a unique stance in today’s market. Read more
US distributors and agents trying to import rapid antibody tests for coronavirus face a number of obstacles. The good news is that FDA has opened up the Emergency Use Authorization (EUA) program to include SARS-CoV-2 (the virus) and COVID-19 (the disease), expediting time to market. Read more
The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us todayContact us